Best-Selling Drugs Of 2019 Ten blockbuster medicines booked
combined sales of $92.5bn in 2019. We examine the drugs that
command the greatest revenues globally. Which therapeutic areas
include the most lucrative blockbusters, which companies enjoy the
spoils, and which drugs are new to the top 10? And what is the
position of these products on the all-important US market?
TOP 10TOP 10 LEAGUE TABLE
Rituxan(rituximab)
Avastin(bevacizumab)
Enbrel(etanercept)
Eylea(aflibercept)
Eliquis(apixaban)
Opdivo(nivolumab)
Imbruvica(ibrutinib)
Revlimid(lenalidomide)
Keytruda(pembrolizumab)
Humira(adalimumab)
RANK
1
2
3
4
5
6
7
8
9
10
% CHANGE
-3.8
+54.6
-3.2
+30.3
+4.7
+23.2
+11.8
-3.6
+0.7
-6.4
19.620.4
11.17.2
9.49.7
8.16.2
8.07.6
7.96.4
7.56.7
7.27.5
7.17.1
6.57.0
KEY 2019 Sales 2018 Sales
2019
vs
2018
+7%CHANGEIN TOTAL SALES
$92.5bn$85.8bn
TO 11TH PLACEfrom 10th
TO 13TH PLACEfrom 5th
JOINING THE TOP 10
TO 6TH PLACEfrom 11th
TO 4TH PLACEfrom 12th
DEPARTING THE TOP 10
BIOLOGICS DOMINATE, IN CANCER AND AUTOIMMUNE DISORDERS
2018Sales
18%
2019Sales
27%
73%$67.0bn
82%$70.7bn
Small Molecules BiologicsKEY
4Autoimmune/Immunology
¢ Humira¢ Imbruvica¢ Enbrel¢ Rituxan
1Cardiovascular
¢ Eliquis
2Ophthalmology
¢ Eylea¢ Humira
6Oncology
¢ Keytruda¢ Revlimid¢ Imbruvica¢ Opdivo¢ Avastin¢ Rituxan
THERAPY AREAS
AbbVie$33.3bn
Humira 58%Imbruvica 14%
Ono PharmaceuticalJPY227bn
Opdivo 39%
Merck & Co$46.8bn
Keytruda 24%
Amgen$23.4bn
Enbrel 22%
RocheCHF61.5bn
Avastin 12%Rituxan 11%
Pfizer$51.8bn
Enbrel 3%Eliquis 8%
RegeneronPharmaceuticals
$7.9bn
Eylea 59%
Bristol-Myers Squibb$26.1bn
Eliquis 30%Opdivo 28%
Revlimid* 5%
Company Name, Total RevenuesKEY
Percentage figure = product's contribution to total
revenues*from 20 November 2019 following acquisition of Celgene
WHICH COMPANIES RELY MOST HEAVILY ON TOP 10 DRUGS?
Only brand with a majority
of ex-US sales
SALES AND PRICE RISES IN US
*AWP unit list price in red book; AWP = average wholesale price;
figures calculated based on prices listed for most of each year
$59.2bnTotal US Sales
62%Average proportion
of sales represented by USfor top 10 drugs in 2019
RituxanAvastinEnbrelEyleaEliquisOpdivoImbruvicaRevlimidKeytrudaHumira
24%$4,756m
43%$4,779m
33%$3,081m
33%$2,700m
46%$3,662m
40%$3,174m
38%$2,896m
30%$2,163m
57%$4,080m
31%$2,002m
69%$4,517m
+0.0%
43%$3,038m
+0.0%
70%$5,050m
+6.2%
62%$4,644m
+0.0%
60%$4,755m
+6.0%
54%$4,344m
+3.0%
67%$5,385m
+6.2%
67%$6,297m
+3.5%
57%$6,305m
+1.5%
76%$14,864m
+7.4% KEY US Rest of world% AWP increase from 2018 to 2019
indicated at top of each bar
Humira
Keytruda
Revlimid
Imbruvica
Opdivo
Eliquis
Eylea
Enbrel
Avastin
Rituxan
2000 2005 2010 2015 2020 2025
US MARKET EXCLUSIVITY TIMELINE
201
9Only two faced US biosimilar/generic competition in 2019
*expected loss of US exclusivity according to Datamonitor
Healthcare
202520242023202220212020
Revlimid
Total
CAGR
$46.3bn $49.0bn $49.5bn $47.2bn $45.0bn $43.2bn
Humira
Keytruda
4.1%
-7.7%
6.8%
GLOBAL SALES OUTLOOK: TOP THREEKeytruda ispoised to overtake
Humira in 2023
Source: Pharmavitae/Datamonitor Healthcare
General sources: Datamonitor Healthcare, Company Annual
Reports
ID: 950184
